Belvedere Trading’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.08M Buy
6,501
+6,261
+2,609% +$1.03M ﹤0.01% 144
2025
Q4
$38.3K Buy
+240
New +$33K ﹤0.01% 680
2025
Q2
Sell
-533
Closed -$28.3K 922
2025
Q1
$32.5K Buy
533
+326
+157% +$27.8K ﹤0.01% 516
2024
Q4
$18.6K Buy
207
+115
+125% +$13.5K ﹤0.01% 690
2024
Q3
$11.8K Buy
+92
New +$12K ﹤0.01% 630
2023
Q3
Sell
-541
Closed -$64.1K 817
2023
Q2
$64.1K Sell
541
-876
-62% -$109K ﹤0.01% 513
2023
Q1
$139K Buy
+1,417
New +$192K ﹤0.01% 403
2022
Q4
Sell
-4,879
Closed -$687K 1175
2022
Q3
$687K Buy
+4,879
New +$894K 0.02% 54

Other funds holding LABU

Belvedere Trading's LABU Position: Q1 2026 in Review

Belvedere Trading increased its Direxion Daily S&P Biotech Bull 3X ETF (LABU) stake by 2,609% in Q1 2026, buying an estimated $1.03M and bringing the position to 6,501 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #144.

Belvedere Trading first reported a position in LABU in Q3 2022 and has held it in 8 quarters since. 33 funds tracked by Wall St. Rank hold LABU as of Q1 2026.

  • Belvedere Trading held 6,501 shares of Direxion Daily S&P Biotech Bull 3X ETF worth $1.08M as of Q1 2026.
  • Belvedere Trading bought 6,261 Direxion Daily S&P Biotech Bull 3X ETF shares in Q1 2026, an estimated $1.03M.
  • Direxion Daily S&P Biotech Bull 3X ETF made up ﹤0.01% of Belvedere Trading's portfolio in Q1 2026, its #144 holding.
  • Belvedere Trading first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q3 2022 and has held it in 8 quarters since.
  • 33 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q1 2026.

Based on Belvedere Trading's 13F filing for Q1 2026, filed 12 May 2026.